Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — H1 FY2026 Earnings Presentation
14 slides from Nova Eye Medical's earnings presentation, March 2026
Slide 1: Nova Eye Medical Limited (ASX:EYE) Investor presentation on half-year results
Nova Eye Medical Limited (ASX:EYE) Investor presentation on financial results for the 6 months ended 31 December 2025 March 2026 nova-eye.com | 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any st
Slide 3: The Interventional Glaucoma Market Size & Our Position
The Interventional Glaucoma Market Size & Our Position Pharma spend~ US$4.3B – Device market US$944M 84M declining 1) due to poor (2025) → US$1.6B (2030), People with compliance low QOL CAGR 10.6%(1) growing as a open - angle glaucoma progressively being displaced better alternative to pharma by dev
Slide 4: Competitive Position in the U.S.
Competitive Position in the U.S. iTrack Advance: FDA-cleared 2023; Why Do Surgeons Choose iTrack Advance? no implant, no foreign material • Procedure: Canaloplasty – restores natural drainage • Complements cataract surgery; (“angioplasty of the eye”). preserves tissue • FDA approved to treat glaucom
Slide 5: Nova Eye Infrastructure
Nova Eye Infrastructure Recruit and train sales representatives to take the message to surgeons. Sales rep recruitment rate is a function of Company strategy to provide BOTH growth and EBITDA positive. Sales management: sales rep recruitment and motivation, territory EXECUTE management for growth, s
Slide 6: Highlighting the Outcomes of Execution
Highlighting the Outcomes of Execution ✓ Record revenue of A$16.7 million for the half up 31% on pcp ✓ Six consecutive halves of USA sales growth at a CAGR of ~40% ✓ LTM global sales of A$32 million up 24%, 3x Focus for 2026 times higher than industry growth rate of Continue to increase ~8% U.S. pro
Slide 7: Regional Performance Summary (US$'000's)
Regional Performance Summary (US$’000’s) H1FY25 H1FY26 Growth on (6 mths to Dec (6 mths to Dec Half PCP H1FY26 2024) 2025) A$000’ US$000’s US$000’s (CC US$) USA 6,476 8,655 32% 13,178 Germany 870 877 1% 1,350 Direct 7,346 9,532 30% 14,528 ROW 329 816 148% 1,256 Sales (excl China) 7,675 10,348 35% 15
Slide 8: Last 12 Months (LTM) Revenue by Region
Last 12 Months (LTM) Revenue by Region LTM Dec 2024 LTM Dec 2025 LTM Dec 2025 Growth (US$’000’s) (US$’000’s) (A$’000’s) (1) USA 12,777 16,272 27% 25,033 Germany 1,720 1,835 7% 2,823 Direct 14,497 18,107 25% 27,856 ROW 1,020 1,788 75% 2,750 Sales (excl China) 15,516 19,895 28% 30,606 China 1,385 1,05
Slide 9: USA Sales Growth Summary
USA Sales Growth Summary Six Consecutive Halves of USA Sales Growth 10,000,000 9,000,000 8,000,000 Revenue in US$ 7,000,000 6,000,000 5,000,000 4,000,000 3,000,000 2,000,000 1,000,000 - H1FY23 H2FY23 H1FY24 H2FY24 H1FY25 H2FY25 H1FY26 • Six consecutive halves of sales growth since the launch of iTra
Slide 10: Cash outflow from operations
Cash outflow from operations Q2FY26 Q2FY26 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1FY26 reported underlying 500 - Cash Outlow in A$000s per qtr -500 -1,000 -1,500 -2,000 -2,500 -3,000 • Group cash outflow from operations for the quarter to December 2025 was A$1.0 million. This
Slide 11: Continued EBITDA improvement
Continued EBITDA improvement EBITDA (loss) in US$ '000s sales EBITDA 12,000 10,951 10,393 10,000 8,565 8,384 8,000 6,673 5,698 5,575 6,000 4,000 2,000 - (2,000) (4,000) (6,000) H1FY23 H2FY23 H1FY24 H2FY24 H1FY25 H2FY25 H1FY26 • Substantial improvement in the operating result compared with H1FY25. Th
Slide 12: Progress on Guidance – Delivering on Promises
Progress on Guidance – Delivering on Promises Guidance Most Recent Guidance Scorecard Progress Confirmed • Sales revenue (excl China) for the 12 months ended 31 Yes December 2025 of US$19.9 million (A$ 30.6 million) at Sales revenue (ex-China): US$21 - 24 28% growth exceeds minimum guidance growth r
Slide 13: Detailed Operating Result
Detailed Operating Result US$'000's A$'000's H1FY25 H1FY26 H1FY25 H1FY26 Net increase in opex in H1FY26 compared with H1FY25 due to: Revenue 8,468 10,951 12,925 16,712 COGS (2,878) (3,273) (4,370) (4,995) • Higher variable sales commissions Gross Margin 5,590 7,678 8,555 11,717 driven by revenue gro
Slide 14: Tom Spurling, Mark Flynn
Tom Spurling Mark Flynn Managing Director Investor Relations +61 8 8360193 +61 416 068 733 tspurling@nova-eye.com mflynn@nova-eye.com nova-eye.com | 14